{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T03:21:24Z","timestamp":1788664884562,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jad.2024.05.116","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T18:31:53Z","timestamp":1716489113000},"page":"421-426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS)"],"prefix":"10.1016","volume":"360","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4013-1112","authenticated-orcid":false,"given":"Angela T.H.","family":"Kwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Rosenblat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo B.","family":"Mansur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2024.05.116_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2023.107650","article-title":"National Institute on Drug Abuse (NIDA) research priorities to support the development of incentive-based treatments for substance use disorders","volume":"176","author":"Aklin","year":"2023","journal-title":"Prev. Med."},{"issue":"25","key":"10.1016\/j.jad.2024.05.116_bb0010","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa2302399","article-title":"Ketamine versus ECT for nonpsychotic treatment-resistant major depression","volume":"388","author":"Anand","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jad.2024.05.116_bb0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/00952990.2020.1808982","article-title":"Ketamine-facilitated behavioral treatment for cannabis use disorder: a proof of concept study","volume":"47","author":"Azhari","year":"2021","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.jad.2024.05.116_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2021.114289","article-title":"A systematic review and meta-analysis of the efficacy of the long-term treatment and support of substance use disorders","volume":"285","author":"Beaulieu","year":"2021","journal-title":"Soc. Sci. Med."},{"key":"10.1016\/j.jad.2024.05.116_bb0025","series-title":"Drug Approvals and Databases","author":"Center for Drug Evaluation, & Research","year":"2022"},{"key":"10.1016\/j.jad.2024.05.116_bb0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.euroneuro.2023.04.011","article-title":"Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: a viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study","volume":"74","author":"Chiappini","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"11","key":"10.1016\/j.jad.2024.05.116_bb0035","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1176\/appi.ajp.2019.18101123","article-title":"A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial","volume":"176","author":"Dakwar","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2024.05.116_bb0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","article-title":"A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial","volume":"177","author":"Dakwar","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2024.05.116_bb0045","doi-asserted-by":"crossref","first-page":"8992697","DOI":"10.1155\/2022\/8992697","article-title":"The incidental resolution of severe alcohol use disorder during Esketamine treatment of major depressive disorder: a case report","volume":"2022","author":"Faruqui","year":"2022","journal-title":"Case Reports in Psychiatry"},{"key":"10.1016\/j.jad.2024.05.116_bb0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12982-015-0037-4","article-title":"Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology","volume":"12","author":"Fedak","year":"2015","journal-title":"Emerg. Themes Epidemiol."},{"issue":"2","key":"10.1016\/j.jad.2024.05.116_bb0055","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2021.21030277","article-title":"Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder","volume":"179","author":"Grabski","year":"2022","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2024.05.116_bb0060","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1038\/s41380-021-01167-1","article-title":"Unraveling the opioid actions of S-ketamine and R-ketamine: comment on Bonaventura et al [Review of unraveling the opioid actions of S-ketamine and R-ketamine: comment on Bonaventura et al]","volume":"26","author":"Heifets","year":"2021","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2024.05.116_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci13060909","article-title":"The role of ketamine in the treatment of bipolar depression: a scoping review","volume":"13","author":"Jawad","year":"2023","journal-title":"Brain Sci."},{"key":"10.1016\/j.jad.2024.05.116_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2022.113804","article-title":"The safety and efficacy of ketamine NMDA receptor blocker as a therapeutic intervention for PTSD review of a randomized clinical trial","volume":"424","author":"Jumaili","year":"2022","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jad.2024.05.116_bb0075","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.jpsychires.2022.04.035","article-title":"The abuse liability of ketamine: a scoping review of preclinical and clinical studies","volume":"151","author":"Le","year":"2022","journal-title":"J. Psychiatr. Res."},{"issue":"1","key":"10.1016\/j.jad.2024.05.116_bb0080","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/JCP.0000000000000441","article-title":"A new perspective on the anti-suicide effects with ketamine treatment: a Procognitive effect","volume":"36","author":"Lee","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.jad.2024.05.116_bb0085","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.biopsych.2022.12.019","article-title":"Mu opioid receptor activation mediates (S)-ketamine reinforcement in rats: implications for abuse liability","volume":"93","author":"Levinstein","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2024.05.116_bb0090","series-title":"Ketamine Rescues Anhedonia by Cell-type and Input Specific Adaptations in the Nucleus Accumbens","author":"Lucantonio","year":"2023"},{"issue":"7","key":"10.1016\/j.jad.2024.05.116_bb0095","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3390\/brainsci11070856","article-title":"Therapeutic potentials of ketamine and esketamine in obsessive\u2013compulsive disorder (OCD), substance use disorders (SUD) and eating disorders (ED): a review of the current literature","volume":"11","author":"Martinotti","year":"2021","journal-title":"Brain Sci."},{"key":"10.1016\/j.jad.2024.05.116_bb0100","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","article-title":"Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study)","volume":"319","author":"Martinotti","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.jad.2024.05.116_bb0105","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2024.05.116_bb0110","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry: Official Journal of the World Psychiatric Association"},{"key":"10.1016\/j.jad.2024.05.116_bb0115","first-page":"1","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)","author":"McIntyre","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jad.2024.05.116_bb0120","unstructured":"MedDRA. (n.d.). Retrieved May 18, 2024, from https:\/\/www.meddra.org\/."},{"key":"10.1016\/j.jad.2024.05.116_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114911","article-title":"Ketamine use in pediatric depression: a systematic review","volume":"317","author":"Meshkat","year":"2022","journal-title":"Psychiatry Res."},{"issue":"7","key":"10.1016\/j.jad.2024.05.116_bb0130","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/s41380-020-00878-1","article-title":"Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals","volume":"26","author":"Mkrtchian","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2024.05.116_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102127","article-title":"Ketamine for the treatment of major depression: a systematic review and meta-analysis","volume":"62","author":"Nikolin","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"14","key":"10.1016\/j.jad.2024.05.116_bb0140","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa2304145","article-title":"Esketamine nasal spray versus quetiapine for treatment-resistant depression","volume":"389","author":"Reif","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2024.05.116_bb0145","series-title":"Odds Ratio","author":"Tenny","year":"2023"},{"issue":"1","key":"10.1016\/j.jad.2024.05.116_bb0150","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2024.05.116_bb0155","article-title":"Evidence of subgroup differences in meta-analyses evaluating medications for alcohol use disorder: an umbrella review","author":"Wallach","year":"2023","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"12","key":"10.1016\/j.jad.2024.05.116_bb0160","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","article-title":"Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism","volume":"24","author":"Williams","year":"2019","journal-title":"Mol. Psychiatry"},{"issue":"8","key":"10.1016\/j.jad.2024.05.116_bb0165","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1111\/bcp.15581","article-title":"Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)","volume":"89","author":"Woods","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.jad.2024.05.116_bb0170","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00213-022-06118-4","article-title":"Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors","volume":"239","author":"Wulf","year":"2022","journal-title":"Psychopharmacology"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724008590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032724008590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:25:13Z","timestamp":1734395113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032724008590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":34,"alternative-id":["S0165032724008590"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2024.05.116","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS)","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2024.05.116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}